Pterostilbene on metabolic parameters: A randomized, double-blind, and placebo-controlled trial

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Riche, Daniel M ^a,b,c   Riche, Krista D ^a,d   Blackshear, Chad T ^b   McEwen, Corey L ^e   Sherman, Justin J ^a   Wofford, Marion R ^b,c   Griswold, Michael E ^b,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d St Dominic Jackson Memorial Hospital   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GRAPEFRUIT EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENOL DERIVATIVE; PLACEBO; PTEROSTILBENE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENDER; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PROSPECTIVE STUDY; RACE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 84904130284     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/459165     Document Type: Article

References (25)

1. Ervin R. B., Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. National Health Statistics Reports 2009 13 1 7 2-s2.0-69149105495
2. Go A. S., Mozaffarian D., Roger V. L., Benjamin E. J., Berry J. D., Borden W. B., Bravata D. M., Dai S., Ford E. S., Fox C. S., Franco S., Fullerton H. J., Gillespie C., Hailpern S. M., Heit J. A., Howard V. J., Huffman M. D., Kissela B. M., Kittner S. J., Lackland D. T., Lichtman J. H., Lisabeth L. D., Magid D., Marcus G. M., Marelli A., Matchar D. B., McGuire D. K., Mohler E. R., Moy C. S., Mussolino M. E., Nichol G., Paynter N. P., Schreiner P. J., Sorlie P. D., Stein J., Turan T. N., Virani S. S., Wong N. D., Woo D., Turner M. B., Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013 127 1 e6 e245 10.1161/CIR.0b013e31828124ad 2-s2.0-84872091789
3. Centers for Disease Control and Prevention, National Center for Health Statistics,. Compressed Mortality File 1999-2009. CDC WONDER Online Database, compiled for Compressed Mortality File 1999-2009 Series 20, No. 20, 2012. Underlying cause-of-death 1999-2009, 2013, http://wonder.cdc.gov/mortSQl.html
4. Cassidy A., Mukamal K. J., Liu L., Franz M., Eliassen A. H., Rimm E. B., High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation 2013 127 2 188 196 10.1161/CIRCULATIONAHA.112.122408 2-s2.0-84872338139
5. Rimando A. M., Nagmani R., Feller D. R., Yokoyama W., Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor α -isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. Journal of Agricultural and Food Chemistry 2005 53 9 3403 3407 10.1021/jf0580364 2-s2.0-19944410516 (Pubitemid 40758174)
6. Park E. S., Lim Y., Hong J. T., Yoo H. S., Lee C. K., Pyo M. Y., Yun Y. P., Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascular Pharmacology 2010 53 1-2 61 67 10.1016/j.vph.2010.04.001 2-s2.0-77952544683
7. Das D. K., Sato M., Ray P. S., Maulik G., Engelman R. M., Bertelli A. A. E., Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs under Experimental and Clinical Research 1999 25 2-3 115 120 2-s2.0-0033034560 (Pubitemid 29257603)
8. Tugwood J. D., Aldridge T. C., Lambe K. G., Macdonald N., Woodyatt N. J., Peroxisome proliferator-activated receptors: stuctures and function. Annals of the New York Academy of Sciences 1996 804 252 265 10.1111/j.1749-6632.1996. tb18620.x 2-s2.0-0030454445 (Pubitemid 27056614)
9. McCormack D., McFadden D., A review of pterostilbene antioxidant activity and disease modification. Oxidative Medicine and Cellular Longevity 2013 2013 15 575482 10.1155/2013/575482 2-s2.0-84877270689
10. Shaul P. W., Regulation of endothelial nitric oxide synthase: Location, location, location. Annual Review of Physiology 2002 64 749 774 10.1146/annurev.physiol.64.081501.155952 2-s2.0-0036199988 (Pubitemid 34259248)
11. Lin H. S., Yue B. D., Ho P. C., Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomedical Chromatography 2009 23 12 1308 1315 10.1002/bmc.1254 2-s2.0-71649110385
12. Kapetanovic I. M., Muzzio M., Huang Z., Thompson T. N., McCormick D. L., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemotherapy and Pharmacology 2011 68 3 593 601 10.1007/s00280-010-1525-4 2-s2.0-80054014686
13. Belcaro G., Ledda A., Hu S., Cesarone M. R., Feragalli B., Dugall M., Grape seed procyanidins in pre- and mild hypertension: a registry study. Evidence-Based Complementary and Alternative Medicine 2013 2013 5 313142 10.1155/2013/313142
14. Feringa H. H., Laskey D. A., Dickson J. E., Coleman C. I., The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. Journal of the American Dietetic Association 2011 111 8 1173 1181 10.1016/j.jada.2011.05.015 2-s2.0-79960807887
15. Riche D. M., McEwen C. L., Riche K. D., Sherman J. J., Wofford M. R., Deschamp D., Griswold M., Analysis of safety from a human clinical trial with pterostilbene. Journal of Toxicology 2013 2013 5 463595 10.1155/2013/463595 2-s2.0-84874620782
16. Gottumukkala V. S., Masna M., Hindupur R. M., Thatipally S., Inventors, aptuit laurus private limited, assignee. X. World patent WO, 2010/0101578 A2, July 2009
17. Jones D. W., Appel L. J., Sheps S. G., Roccella E. J., Lenfant C., Measuring blood pressure accurately: new and persistent challenges. The Journal of the American Medical Association 2003 289 8 1027 1030 10.1001/jama.289.8.1027 2-s2.0-0037466925 (Pubitemid 37432936)
18. Rasmussen C. B., Glisson J. K., Minor D. S., Dietary supplements and hypertension: potential benefits and precautions. The Journal of Clinical Hypertension 2012 14 467 471 10.1111/j.1751-7176.2012.00642.x
19. Nahas R., Complementary and alternative medicine approaches to blood pressure reduction: an evidence-based review. Canadian Family Physician 2008 54 11 1529 1533 2-s2.0-56549103740
20. Goldberg R. B., Kendall D. M., Deeg M. A., Buse J. B., Zagar A. J., Pinaire J. A., Tan M. H., Khan M. A., Perez A. T., Jacober S. J., A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 7 1547 1554 10.2337/diacare.28.7.1547 2-s2.0-21544466158 (Pubitemid 40923063)
21. Farnier M., Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Diabetes Research and Clinical Practice 2005 70 20 25
22. Negro R., Mangieri T., Dazzi D., Pezzarossa A., Hassan H., Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Vascular Health and Risk Management 2008 4 991 1000
23. Stone N. J., Robinson J., Lichtenstein A. H., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 10.1161/01.cir.0000437738.63853.7a
24. James P. A., Oparil S., Carter B. L., 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth Joint National Committee (JNC 8). The Journal of the American Medical Association 2014 311 5 507 520 10.1001/jama. 2013.284427
25. Vollmer W. M., Appel L. J., Svetkey L. P., Moore T. J., Vogt T. M., Conlin P. R., Proschan M., Harsha D., Comparing office-based and ambulatory blood pressure monitoring in clinical trials. Journal of Human Hypertension 2005 19 1 77 82 10.1038/sj.jhh.1001772 2-s2.0-12744261483